Manufacturers’ Group Is Not Satisfied With FDA In-Vitro Diagnostics Office
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic manufacturers have not seen the improved review times they expected from the founding of the Office of In Vitro Diagnostic Device Evaluation & Safety (OIVD) in 2002, according to the chief counsel for the Association of Medical Diagnostic Manufacturers (AMDM)
You may also be interested in...
Senate Committee Calls For Greater Oversight Of At-Home Genetic Tests
A Senate leader prodded FDA and CMS officials to strengthen oversight of genetic tests offered directly to consumers via the internet following the release of a report questioning the validity of some of those tests
Senate Committee Calls For Greater Oversight Of At-Home Genetic Tests
A Senate leader prodded FDA and CMS officials to strengthen oversight of genetic tests offered directly to consumers via the internet following the release of a report questioning the validity of some of those tests
FDA’s Accelerated Review Of Flu Test Offers A Model For Future Products
FDA's rapid review of a laboratory test that can aid in the diagnosis of avian influenza demonstrates a pathway that could be used for the introduction of other much-needed diagnostics, the agency suggests